百利天恒董事长朱义：将投资20亿元，实现成都制造、供应全球

Group 1 - The company plans to invest 2 billion yuan in Chengdu to establish a global innovative pharmaceutical supply base [1] - Baile Tianheng is a comprehensive biopharmaceutical company focused on innovative drug research and development, with capabilities spanning from early research to global clinical trials and large-scale production [3] - The company has developed leading platforms for innovative ADC and antibody drugs, and was included in the "2024 Forbes China Innovation Power 50" list [4] Group 2 - Chengdu's biopharmaceutical industry is rapidly developing, becoming a significant national base, ranking fourth in pharmaceutical manufacturing scale nationwide and first in the Midwest [4] - From 2016 to 2024, Chengdu approved a total of 637 drug listings, ranking second among all cities in China [4] - The company believes that Chengdu will become a leading area for cancer treatment drug research and a major base for global commercial drug supply [4]